ArriVent BioPharma Inc., a clinical-stage company focused on the global development of biopharmaceutical therapeutics, has announced that topline data from the FURVENT Phase 3 study of firmonertinib monotherapy in first-line EGFR exon20 insertion mutant non-small cell lung cancer (NSCLC) is projected to be available in early 2026. The study, which completed enrollment in the first quarter of 2025, aims to assess progression free survival $(PFS)$ by blinded independent central review according to RECIST 1.1 criteria. Firmonertinib has previously received FDA Breakthrough Therapy Designation for this patient population, highlighting the potential significance of the upcoming data. The results of the FURVENT study have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.